Janet Dancey

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Issues and progress with protein kinase inhibitors for cancer treatment
    Janet Dancey
    Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, National Cancer Institute, 6130 Executive Blvd, Room 7131, Rockville, Maryland 20852, USA
    Nat Rev Drug Discov 2:296-313. 2003
  2. ncbi request reprint Epidermal growth factor receptor inhibitors in clinical development
    Janet Dancey
    Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
    Int J Radiat Oncol Biol Phys 58:1003-7. 2004
  3. ncbi request reprint Inhibitors of the mammalian target of rapamycin
    Janet E Dancey
    Investigational Drug Branch CTEP DCTD, National Cancer Institute, 6130 Executive Boulevard, Room 7131 Rockville, MD 20852, USA
    Expert Opin Investig Drugs 14:313-28. 2005
  4. ncbi request reprint Recent advances of molecular targeted agents: opportunities for imaging
    Janet E Dancey
    Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 2:601-9. 2003
  5. ncbi request reprint Strategies for optimizing combinations of molecularly targeted anticancer agents
    Janet E Dancey
    Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard EPN 7131, Rockville, Maryland 20852, USA
    Nat Rev Drug Discov 5:649-59. 2006
  6. ncbi request reprint Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow
    Janet E Dancey
    Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, 6130 Executive Boulevard, Room 7131, Rockville, MD 20852, USA
    Cancer Cell 5:411-5. 2004
  7. ncbi request reprint Epidermal growth factor receptor inhibitors in non-small cell lung cancer
    Janet E Dancey
    Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland 20852, USA
    Drugs 67:1125-38. 2007
  8. ncbi request reprint Clinical development of mammalian target of rapamycin inhibitors
    Janet E Dancey
    Cancer Treatment Evaluation Program, Division of Cancer Treatment and Diagnosis, Investigational Drug Branch CTEP DCTD NCI, 6130 Executive Boulevard, EPN 7131, Rockville, MD 20854, USA
    Hematol Oncol Clin North Am 16:1101-14. 2002
  9. ncbi request reprint Agents targeting ras signaling pathway
    J E Dancey
    Cancer Therapy Evaluation Program, National Cancer Institute, 6130 Executive Blvd, EPN 7131, Rockville, MD 20852, USA
    Curr Pharm Des 8:2259-67. 2002
  10. ncbi request reprint mTOR inhibitors in hematologic malignancies
    Janet E Dancey
    Investigational Drug Branch, Cancer Treatment Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard, Rockville, MD 20854, USA
    Clin Adv Hematol Oncol 1:419-23. 2003

Detail Information

Publications39

  1. ncbi request reprint Issues and progress with protein kinase inhibitors for cancer treatment
    Janet Dancey
    Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, National Cancer Institute, 6130 Executive Blvd, Room 7131, Rockville, Maryland 20852, USA
    Nat Rev Drug Discov 2:296-313. 2003
    ..Here, we consider the crucial issues in the development of kinase inhibitors for cancer, and discuss strategies to address the challenges raised by these issues in the light of preclinical and clinical experiences so far...
  2. ncbi request reprint Epidermal growth factor receptor inhibitors in clinical development
    Janet Dancey
    Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
    Int J Radiat Oncol Biol Phys 58:1003-7. 2004
    ..Ongoing and future studies must address issues related to the selection of patients for study, dose and schedule of administration, monotherapy vs. combination treatment, and combinations with standard and investigational agents...
  3. ncbi request reprint Inhibitors of the mammalian target of rapamycin
    Janet E Dancey
    Investigational Drug Branch CTEP DCTD, National Cancer Institute, 6130 Executive Boulevard, Room 7131 Rockville, MD 20852, USA
    Expert Opin Investig Drugs 14:313-28. 2005
    ..Questions remain regarding optimal dose, schedule, patient selection and combination strategies for this novel class of agents...
  4. ncbi request reprint Recent advances of molecular targeted agents: opportunities for imaging
    Janet E Dancey
    Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 2:601-9. 2003
    ..The purpose of this review is to summarize recent results from trials of selected targeted agents and to suggest roles imaging may play in the further development of these and other targeted agents...
  5. ncbi request reprint Strategies for optimizing combinations of molecularly targeted anticancer agents
    Janet E Dancey
    Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard EPN 7131, Rockville, Maryland 20852, USA
    Nat Rev Drug Discov 5:649-59. 2006
    ..Issues that pose challenges to the rational preclinical and clinical evaluation of such combinations will be described, and possible approaches to overcoming these challenges will be discussed...
  6. ncbi request reprint Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow
    Janet E Dancey
    Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, 6130 Executive Boulevard, Room 7131, Rockville, MD 20852, USA
    Cancer Cell 5:411-5. 2004
    ..Two recent studies have identified somatic mutations in EGFR that confer its sensitivity to gefitinib in vitro and correlate strongly with patients' clinical response to the inhibitor...
  7. ncbi request reprint Epidermal growth factor receptor inhibitors in non-small cell lung cancer
    Janet E Dancey
    Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland 20852, USA
    Drugs 67:1125-38. 2007
    ..Additional evaluation to determine optimal dose/schedule of the agents combined with standard treatments and with other targeted agents in appropriately selected patients are areas of active research...
  8. ncbi request reprint Clinical development of mammalian target of rapamycin inhibitors
    Janet E Dancey
    Cancer Treatment Evaluation Program, Division of Cancer Treatment and Diagnosis, Investigational Drug Branch CTEP DCTD NCI, 6130 Executive Boulevard, EPN 7131, Rockville, MD 20854, USA
    Hematol Oncol Clin North Am 16:1101-14. 2002
    ..The challenge to investigators is to efficiently determine what role this class of agent will play in the treatment of cancer patients...
  9. ncbi request reprint Agents targeting ras signaling pathway
    J E Dancey
    Cancer Therapy Evaluation Program, National Cancer Institute, 6130 Executive Blvd, EPN 7131, Rockville, MD 20852, USA
    Curr Pharm Des 8:2259-67. 2002
    ..The purpose of this review is to highlight recent advances in the development of these agents...
  10. ncbi request reprint mTOR inhibitors in hematologic malignancies
    Janet E Dancey
    Investigational Drug Branch, Cancer Treatment Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard, Rockville, MD 20854, USA
    Clin Adv Hematol Oncol 1:419-23. 2003
    ....
  11. ncbi request reprint Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial
    Janet Dancey
    Toronto Hospital, Toronto, Canada
    Lung Cancer 43:183-94. 2004
    ..Patients were randomized to docetaxel 100 mg/m2 (n=49) or, after protocol amendment, to docetaxel 75 mg/m2 (n=55), or to BSC (n=100), with Lung Cancer Symptom Scale (LCSS) and/or QLQ-C30 (with LC13 module) assessment every 3 weeks...
  12. pmc Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib
    Laura Vidal
    Princess Margaret Hospital Phase II Consortium, Toronto, Canada
    Head Neck 31:1006-12. 2009
    ....
  13. pmc Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer
    Carter Van Waes
    Head and Neck Surgery Branch, National Institute of Deafness and Communication Disorders, National Institutes of Health, Bethesda, MD, USA
    Int J Radiat Oncol Biol Phys 77:447-54. 2010
    ....
  14. pmc A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 65:383-9. 2010
    ..We designed a phase I study to determine the maximum tolerated dose (MTD) of UCN-01 with prednisone in patients with advanced malignancies...
  15. pmc Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Cancer Research Building I, Baltimore, MD, USA
    Cancer Chemother Pharmacol 61:423-33. 2008
    ....
  16. doi request reprint mTOR signaling and drug development in cancer
    Janet Dancey
    Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College Street, Suite 800, Toronto, ON M5G 0A3, Canada
    Nat Rev Clin Oncol 7:209-19. 2010
    ..Future research should evaluate the optimal drug regimens, schedules, patient populations, and combination strategies for this novel class of agents...
  17. ncbi request reprint Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib
    Mark Agulnik
    Princess Margaret Hospital Phase II Consortium, Toronto, Ontario, Canada
    J Clin Oncol 25:2184-90. 2007
    ..Additional biomarker studies with larger sample sizes are required to elucidate HNSCC patients who may benefit from this targeted therapy...
  18. ncbi request reprint Dose escalation trial designs based on a molecularly targeted endpoint
    Sally Hunsberger
    Biometrics Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Stat Med 24:2171-81. 2005
    ..A limited simulation study is performed and the designs are compared with respect to the dose level at the end of escalation and the number of patients treated on study...
  19. ncbi request reprint Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study
    Lillian L Siu
    Princess Margaret Hospital Phase II Consortium, Toronto, Toronto, Ontario, Canada
    J Clin Oncol 25:2178-83. 2007
    ....
  20. ncbi request reprint New targets for cancer chemotherapy
    Anthony J Murgo
    Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Blvd, Rockville, MD 20852, USA
    Cancer Chemother Biol Response Modif 20:239-72. 2002
  21. pmc Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?
    Lori E Dodd
    Division of Cancer Treatment and Diagnosis, Branches of Biometric Research, Investigational Drug, Cancer Investigations, and Diagnostic Imaging, National Cancer Institute, Rockville, MD 20892, USA
    J Clin Oncol 26:3791-6. 2008
    ..When such designs are not practical, BICR is not recommended as a general strategy for reducing bias. However, BICR may be useful as an auditing tool to assess the reliability of marginally positive results...
  22. doi request reprint Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148
    Amit M Oza
    Princess Margaret Hospital, University Health Network, Bras Family Drug Development Program, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 26:4319-25. 2008
    ..Epidermal growth factor receptor (EGFR) overexpression is common in endometrial cancers and may have a major role in tumor growth and progression. Erlotinib is an orally active, selective inhibitor of EGFR tyrosine kinase activity...
  23. pmc Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study
    Regina I Jakacki
    Children s Hospital of Pittsburgh, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:4921-7. 2008
    ..We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors...
  24. ncbi request reprint Targeting epidermal growth factor receptor--are we missing the mark?
    Janet E Dancey
    Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
    Lancet 362:62-4. 2003
    ..Appropriately designed clinical trials are required to define the optimum dose, schedule, and sequence for these agents in combination with conventional therapies and other targeted agents...
  25. ncbi request reprint Clinical trials referral resource. Current clinical trials of erlotinib
    Janet E Dancey
    National Cancer Institute, Bethesda, MD, USA
    Oncology (Williston Park) 19:1124, 1127-8, 1130 passim. 2005
  26. ncbi request reprint Clinical trials referral resource. Current clinical trials of agents targeting epidermal growth factor receptor
    Janet E Dancey
    National Cancer Institute, Bethesda, MD, USA
    Oncology (Williston Park) 17:819, 826-30, 833-4 passim. 2003
  27. ncbi request reprint Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study
    Najat C Daw
    Department of Hematology Oncology, Mail Stop 260, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 23:6172-80. 2005
    ..Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors...
  28. ncbi request reprint Therapeutic targets: MTOR and related pathways
    Janet E Dancey
    Investigational Drug Branch CTEP DCTD, National Cancer Institute, Rockville, Maryland 20852, USA
    Cancer Biol Ther 5:1065-73. 2006
    ..Future research should evaluate optimal, schedule, patient selection, and combination strategies for this novel class of agents...
  29. ncbi request reprint Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Larry V Rubinstein
    J Natl Cancer Inst 99:1422-3. 2007
  30. ncbi request reprint Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands
    Mark Agulnik
    Princess Margaret Hospital Phase II Consortium, Toronto, Ontario, Canada
    J Clin Oncol 25:3978-84. 2007
    ..This phase II study was conducted to determine the antitumor activity of lapatinib, a dual inhibitor of EGFR and erbB2 tyrosine kinase activity, in MSGTs...
  31. ncbi request reprint UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium
    Stephen Welch
    Princess Margaret Hospital, Toronto, Ontario, Canada M56 2M9
    Gynecol Oncol 106:305-10. 2007
    ..Topotecan is an active agent in ovarian cancer. This phase II study was conducted to investigate the safety and efficacy of topotecan and UCN-01 in patients with advanced ovarian cancer...
  32. ncbi request reprint A Phase 2 study of perifosine in advanced or metastatic breast cancer
    Natasha B Leighl
    Medical Oncology, Princess Margaret Hospital University Health Network, Toronto, ON, Canada
    Breast Cancer Res Treat 108:87-92. 2008
    ..Perifosine, an oral alkylphospholipid structurally related to miltefosine, has marked activity against breast cancer cell lines and xenograft models, with broad spectrum cellular effects...
  33. ncbi request reprint Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC, USA
    J Clin Oncol 23:7178-87. 2005
    ..In addition, plasma concentrations of O6-BG and O6-benzyl-8-oxoguanine were evaluated after O6-BG...
  34. ncbi request reprint Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis
    James E Goin
    DataMedix Corporation, Brookhaven, Pennsylvania, USA
    J Vasc Interv Radiol 16:195-203. 2005
    ..To present the findings of a risk-stratification survival analysis with use of data collected on a heterogeneous group of patients with hepatocellular carcinoma (HCC) treated with TheraSphere...
  35. ncbi request reprint Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap?
    Janet E Dancey
    J Clin Oncol 22:2975-7. 2004
  36. ncbi request reprint Phase II trial of gefitinib in recurrent glioblastoma
    Jeremy N Rich
    Duke University Medical Center, Box 2900, Durham, NC 27710, USA
    J Clin Oncol 22:133-42. 2004
    ..To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma...
  37. ncbi request reprint A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer
    Natasha B Leighl
    Department of Medical Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    Clin Lung Cancer 5:107-12. 2003
    ..2 mg/m2 I.V. every 21 days. Antitumor activity was seen at all dose levels. This combination is well tolerated and has evidence of antitumor activity. A phase II evaluation is ongoing...
  38. ncbi request reprint Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer, Part 2
    Malcolm A Smith
    National Cancer Institute, USA
    Oncology (Williston Park) 16:474, 479-80, 483-4 passim. 2002
  39. ncbi request reprint Accuracy of recorded tumor, node, and metastasis stage in a comprehensive cancer center
    James D Brierley
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Ontario, Canada
    J Clin Oncol 20:413-9. 2002
    ..An audit was performed to determine the accuracy of recorded stage and to act as a baseline before the implementation of an education program...